Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06513949 · ClinicalTrials.gov registry record · Phase 2
Anti-CD14 Treatment With IC14 in Hospitalized ARDS Patients
A Phase 2 study of Acute Respiratory Distress Syndrome and Acute Lung Injury, sponsored by Implicit Bioscience.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
- 2
- Study locations
NCT06513949: Recruiting Phase 2 study of Acute Respiratory Distress Syndrome and Acute Lung Injury, sponsored by Implicit Bioscience.
NCT06513949 is a Phase 2 study of Acute Respiratory Distress Syndrome and Acute Lung Injury that is actively recruiting participants, run by Implicit Bioscience. The registered enrollment target is 56 participants, below the 366-participant average among 31 other Acute Respiratory Distress Syndrome trials with a reported enrollment target (85% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06513949, a Phase 2 study of Acute Respiratory Distress Syndrome and Acute Lung Injury, is actively recruiting participants, sponsored by Implicit Bioscience.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
- 2
- Study locations
Study Summary
Hospitalized patients with ARDS will be randomized to intravenous treatment with a monoclonal antibody against CD14, called IC14, or placebo. They will be followed for 28 days. The primary outcome is the day 4 oxygenation index assessed as a continuous measure.
Primary Outcome
(mean airway pressure x fraction of inspired oxygen \[FiO2\] x100)/ partial pressure of oxygen \[PaO2\]
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL Atibuclimab
Study Locations (2)
Washington
- Harborview Medical Center - Seattle
- University of Washington - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2025-08-15 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
What NCT06513949 shows while recruiting
NCT06513949 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, below the 366-participant average among 31 other Acute Respiratory Distress Syndrome trials with a reported enrollment target (85% lower).
The record links to 4 conditions, with Acute Respiratory Distress Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06513949 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT06513949 about?
NCT06513949 is a clinical study titled "Anti-CD14 Treatment With IC14 in Hospitalized ARDS Patients". Hospitalized patients with ARDS will be randomized to intravenous treatment with a monoclonal antibody against CD14, called IC14, or placebo. They will be followed for 28 days. The primary outcome is the day 4 oxygenation index assessed as a continuous measure.
What is the current status of trial NCT06513949?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2025-08-15. Estimated completion is 2027-12.
What conditions does trial NCT06513949 study?
This clinical trial studies the following conditions: Acute Respiratory Distress Syndrome, Acute Lung Injury, Adult Respiratory Distress Syndrome, Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS).
What interventions are being tested in trial NCT06513949?
The interventions under investigation include: Placebo (OTHER), Atibuclimab (BIOLOGICAL).
Who is sponsoring clinical trial NCT06513949?
This trial is sponsored by Implicit Bioscience, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06513949 being conducted?
This trial has 2 study locations across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Respiratory Distress Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06513949's enrollment target sits among peer trials
56 19th of 31 higher than 12 of 31 other Acute Respiratory Distress Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Respiratory Distress Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)
RECRUITING · Phase 2
-
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab
RECRUITING · Phase 2
-
Phase 2a Multiple Ascending Dose Study in Hospitalized Patients With Pneumonia.
RECRUITING · Phase 2
-
Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)
RECRUITING · Phase 2
-
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab
RECRUITING · Phase 2
-
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI